COVID-19 VACCINATION

Checklist for administration of COVID-19 Vaccine Janssen® (adenoviral vector vaccine Janssen-Cilag)

Before vaccination

| Administrative clarification | • Clarify how the person to be vaccinated is insured (compulsory health insurance/insurance card)  
| • Verify the identity of the person to be vaccinated |
| Clarification of the indication for vaccination | • The Swiss COVID-19 vaccination strategy is based primarily on mRNA vaccines  
• Vaccination with COVID-19 Vaccine Janssen®: Recommended for unvaccinated individuals 18 years of age and older who, for medical reasons, cannot be vaccinated with an mRNA vaccine and for individuals who refuse mRNA vaccines.  
• Contraindications for mRNA vaccines:  
  - Anaphylaxis or severe general reaction to ingredients in the vaccine  
  - Known or probable immediate-type hypersensitivity to polyethylene glycol (PEG, macrogol) or tromethamine (trometamol, TRIS)  
  - Anaphylaxis after the first dose of mRNA vaccine (caution: no data are available on the safety and efficacy after application of one dose of an mRNA vaccine and one dose of COVID-19 Vaccine Janssen®)  
  ➔ Clarification and consultation with a specialist in allergies and clinical immunology recommended |
| Clarification of contraindications | • Known hypersensitivity to ingredients in the vaccine (e.g. polysorbate 80).  
• Individuals with a history of capillary leak syndrome (CLS) |
| Vaccination not currently recommended | 1. Children and adolescents (<18 years)  
2. Pregnant and breastfeeding women |
| Clarification of special precautions | 1. Generally known hypersensitivity reactions/allergies?  
2. Immunodeficiency (congenital, acquired, immunosuppressant treatment, including during cancer treatment)  
  ➔ For immunocompromised individuals a vaccination with mRNA vaccines is generally recommended. Indication for vaccination with COVID-19 Vaccine Janssen® only after a careful benefit/risk assessment (efficacy, tolerability), particularly compared to vaccination with an mRNA vaccine, by the treating specialist and after a corresponding briefing. (vaccination recommendation: link: www.bag.admin.ch/covid-19-dokumente-gesundheitsfachpersonen, available in German and French) |
### Vaccination procedure

#### Current general health/COVID-19 medical history
- Clarify current general health and decide:
  - Can the vaccination proceed today?
  - Acute febrile illness (fever)?
    - Postpone vaccination until the symptoms have subsided
  - Persons with confirmed SARS-CoV-2 infection: Vaccination with one dose recommended promptly from 4 weeks after infection and within 3 months.
    - [Statements and consequences of different types of SARS-CoV-2-tests](https://www.bag.admin.ch/covid-19-dokumente-gesundheitsfachpersonen->English
documents)

#### Client briefing
- Does the person to be vaccinated have any questions?
- Has he/she read the information material?
- Mention possible adverse vaccination reactions (AVRs), and particularly
  - possible allergic reactions
  - signs of thromboembolism and thrombocytopenia:
    - from a few days to 3 weeks after vaccination, symptoms such as severe or persistent headaches, blurred vision, confusion, mood changes, seizures, shortness of breath, chest pain, leg swellings, leg pain, persistent abdominal pain, unusual skin bruising, petechiae.

#### Client consent
- Obtain oral consent to the vaccination from the person to be vaccinated on the basis of an informed consent and to the electronic recording of the vaccination in the data entry system
- Make a written note of the consent to vaccination in the vaccination data sheet/IT tool
- If the person is incapable of giving consent, the consent must be obtained from his/her legal representative

#### Completing the vaccination data sheet/recording in the IT tool
- Enter the relevant details of the person to be vaccinated in the IT tool

#### Preparing the vaccine
- Gently swirl the vaccine vials without shaking, careful handling
- If possible, the stopper should only be pierced once with the needle, and the movement of the needle should be minimised.

#### Administering the vaccine
- One vaccine dose i.m. in deltoid muscle
- For anticoagulated patients: The vaccine is also injected intramuscularly, and subsequent firm compression is important [www.bag.admin.ch/impfplan](http://www.bag.admin.ch/impfplan) (in German, French and Italian)

### After vaccination

#### Explain how to behave in the event of an adverse vaccination reactions (AVRs)
- Tell the client to report any serious or unexpected AVRs to a doctor/pharmacist/vaccination site
- If applicable, give the client a contact number
- Reporting via link to the "ELVIS" reporting system in the IT tool

#### Explain how to behave generally after vaccination
- Expected protection provided by the vaccine appears 3 weeks after injection.
- Continue to follow rules of social distancing and hygiene with the exception of private meetings between fully vaccinated persons (wearing a mask and distancing is not necessary) and events with a certificate (according to the organiser's instructions).
- If a booster vaccination is needed, clients will be informed
- If symptoms consistent with COVID-19 occur, carry out a test (vaccination not 100% effective)
- For vaccinated persons, contact and travel quarantine, as well as certain other health measures at the border, may be waived for a period of 12 months after vaccination (according to cantonal directives and information on the FOPH website: Travel [admin.ch](http://admin.ch))
- No minimal interval to other vaccines is necessary

#### Issuing a vaccination certificate
- Issue the client with a vaccination certificate from the IT tool or make an entry in the vaccination record
- Issue the client with a vaccination certificate from the IT tool or make an entry in the vaccination record
- Affix/enter LOT number in the vaccination certificate
- Provide information on the vaccination certificate (valid from the 22nd day after injection) and issue on request: [COVID certificate](http://admin.ch)

#### Observation time after vaccination
- Trained healthcare personnel and an emergency kit, including adrenaline, must be available in case an allergic reaction occurs.
- Monitor particularly those who experienced problems directly after the injection, e.g. circulatory problems
- All people who are vaccinated should remain on the premises for at least 15 minutes after the injection.